Table 6. Reporting rates of likely myocarditis following Pfizer-BioNTech and Moderna COVID-19 vaccines in Australia, by age and sex (as of 27 March 2022)^a.

Age groupb (years)	Pfizer-BioNTech (number of events per 100 000 doses)c				Moderna (number of events per 100 000 doses)c
	Both doses		2nd dose		Both doses		2nd dose
	Male	Female	Male	Female	Male	Female	Male	Female
12–17	7.6	1.4	12.2	2.3	10.8	3.0	20.5	5.1
18–29	4.2	1.2	4.5	2.0	8.6	1.1	17.8	2.4
30–39	1.6	0.6	2.0	0.7	2.4	0.6	5.1	0
40–49	0.7	0.5	1.0	1.0	1.4	0.3	1.7	0
50–59	0.4	0.3	0.1	0.3	0.3	0.9	0	2.5
60–69	0.1	0.3	0	0.4	0	0.3	0	0
≥ 70	0	0.1	0	0.4	0	0.2	0	0
Total	2.0	0.7	3.9	1.1	3.2	0.8	9.6	1.9

^a Likely myocarditis includes cases classified as levels 1–3. Level 1 cases are confirmed to be myocarditis based on strong clinical evidence including the patient’s symptoms, and results of tests and imaging indicating a diagnosis of myocarditis. Level 2 cases are probable myocarditis based on a combination of symptoms and routine tests for heart conditions. Level 3 cases are possible myocarditis based on symptoms and a doctor’s report that myocarditis is the most likely diagnosis in the absence of medical tests and investigations. For all cases of suspected myocarditis, where possible, other known causes of the patient’s symptoms or test results are ruled out before cases are classified.

^b As of 27 March 2022, no likely cases of myocarditis had been reported in children aged 5–11 years.

^c The rate includes cases of myocarditis that occurred after vaccination but may not be vaccine-related. To comply with the Therapeutic Goods Administration’s copyright, the rates are expressed per 100 000 doses administered. To comply with the Therapeutic Goods Administration’s copyright, the rates are expressed per 100 000 doses administered.

Source: Data are reproduced with permission from the Therapeutic Goods Administration, Australian Government. (14)